The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.

ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.

ScinoPharm receives US FDA approval for glatiramer acetate injection to treat multiple sclerosis: Taiwan Tuesday, January 6, 2026, 14:00 Hrs [IST] ScinoPharm Taiwan, a professiona ...

Taiwanese drugmaker ScinoPharm (TWSE: 1789) has secured approval from the US Food and Drug Administration for its glatiramer ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Swiss pharma giant Roche won approval from the ...

Biologic drugs are typically given as infusions that can take an hour or longer. The FDA has approved injectable versions of two biologic Roche drugs, one for multiple sclerosis and the other for ...

The US Food and Drug Administration (FDA) has added a boxed warning to the label of multiple sclerosis drug glatiramer acetate about the risk of anaphylaxis. From December 1996 through May 2024, 82 ...

Copaxone and its generic form, Glatopa, may lead to anaphylaxis even in patients who’ve been taking the medication for months without incident. The FDA warns that the injectable MS drugs Copaxone and ...

Most of the patients in these reported cases experienced anaphylaxis within 1 hour after injection. Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug ...

NICE has recommended natalizumab for adults with highly active RRMS, citing pregnancy suitability, biosimilar value and NHS ...

Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) ...